Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hematopoietic stems and in vivo animal transplantation. Through this collaboration, the two companies aim to demonstrate a method for large-scale expansion of high-quality iPSC-HSPCs - addressing key manufacturing challenges in the development of iPSC-derived blood and immune cell therapies.